Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS

Harrow (HROW) is rapidly scaling its branded ophthalmic franchise led by Vevye, which the author estimates at ~$100M in 2025 and conservatively projects to $300M in 2026 following a VAFA access program, doubling of the salesforce to 100 reps, and Tier 1 formulary placement at CVS that displaced Xiidra. The author models 2026 company revenue of ~$570M (Vevye $300M, Iheezo $100M, Immy $80M, other products $90M), EBITDA around $200M and free cash flow of roughly $4/share, expects leverage to fall below 1x in 2026 and forecasts $10/share FCF in 2027, implying a 2026 price target of $175. Key risks noted include tariff/MFN policy uncertainty, inventory/regulatory hiccups at the compounding business, and macro market drawdowns; however, the piece argues operating leverage, improving coverage, and product mix make the stock materially undervalued at current levels.

Analysis

Market structure: HROW (Vevye) is the clear beneficiary of a fast-expanding DED market (28% CAGR since 2024) with a low-capital VAFA model that converts uninsured patients and forces PBM re-pricing; winners include HROW, sales-heavy competitors that adopt similar access programs, and PBMs that secure re-priced Tier 1 economics (CVS). Losers are legacy DED franchises (Xiidra/Restasis-like incumbents) and small competitors without direct prescriber reach; a shift to Tier 1 across 3 PBMs would raise HROW ASP by $20–$40 and materially reallocate ~$350M incumbent revenue over 12–24 months.

Risk assessment: Key tail risks are regulatory (MFN/drug pricing reforms within 6–18 months), product setbacks (safety/label changes), and execution (failure to scale reps from 50→100). Hidden dependencies include VAFA’s sustainability if PBMs push aggressive net-cost audits and royalty/service rates on Imprimis distribution; monitor leverage falling below 1x and FCF per share (target thresholds: $4/sh 2026, $10/sh 2027) as binary credibility triggers. Catalysts: CVS Tier‑1 rollout (Jan 2026), Q1–Q2 2026 PBM expansions, and quarterly ASP inflection points.

Trade implications: Tactical long HROW exposure is high-conviction given 2026 Vevye upside (author’s $300M est) — use staged buys into Q1–Q2 2026 results; consider 12‑18 month call spreads to capture de‑levering/ASP re‑rate. Relative plays: long HROW vs short BLCO (competitor Miebo) sized 1–2% notional to capture share reallocation if HROW retains faster coverage expansion. Hedge macro beta with index puts if broad market drawdown risk >20%.

Contrarian angles: Consensus assumes linear adoption — miss is underestimating VAFA’s bargaining leverage with PBMs and the incremental TAM conversion from ~1M to multi‑million treated patients; conversely upside is capped if MFN or aggressive PBM clawbacks arrive. Historical parallel: rapid formulary displacement mirrors specialty Rx shifts (e.g., anti‑TNFs) where 12–24 month market-share moves were permanent; unintended consequences include PBMs demanding deeper rebates that compress HROW gross margins if scale expectations falter.

Key Decisions for Investors

• Establish an initial 2–3% long position in HROW at current levels (~$40) and scale to 4–5% if FY2026 guidance confirms Vevye ≥ $250M and company FCF ≥ $3.5/share; trim half of position if post‑2026 FCF < $2/share or net debt/EBITDA remains >2x by Q4 2026.
• Buy a directional options spread to lever upside: purchase a 12‑month HROW call spread (e.g., Jan 2027 long 50C / short 100C) sized to equal ~1% portfolio equity exposure to capture de‑levering and ASP re‑rate while capping premium outlay.
• Initiate a 1–2% pair trade: long HROW / short BLCO (equal dollar) to exploit relative share gains in DED over 6–12 months; unwind if BLCO announces equivalent PBM Tier‑1 wins or HROW fails to convert CVS coverage into ASP uplift within two consecutive quarters.
• Monitor regulatory catalysts closely: if CMS/FTC produce MFN language or PBM rebate/clawback proposals in the next 60–180 days that explicitly target small‑company access programs, reduce HROW exposure by 50% until rules and legal timelines are clear.